CG
RMD icon

CFO4Life Group’s ResMed RMD Stock Holding History

CFO4Life Group’s Portfolio RMD Stock Details RMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$443K Sell
2,272
-52
-2% -$10.8K 0.06% 141
2026
Q1 		$522K Sell
2,324
-225
-9% -$56.1K 0.08% 120
2025
Q4 		$614K Sell
2,549
-100
-4% -$25.6K 0.09% 112
2025
Q3 		$725K Buy
2,649
+9
+0.3% +$2.46K 0.11% 99
2025
Q2 		$681K Buy
2,640
+121
+5% +$28.9K 0.11% 100
2025
Q1 		$564K Sell
2,519
-77
-3% -$18K 0.09% 111
2024
Q4 		$594K Buy
+2,596
New +$625K 0.1% 106

Other funds holding RMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

CFO4Life Group's RMD Position: Q2 2026 in Review

CFO4Life Group reduced its ResMed (RMD) stake by 2.2% in Q2 2026, selling an estimated $10.8K and leaving 2,272 shares worth $443K. The position accounts for 0.06% of the portfolio, ranked #141.

CFO4Life Group first reported a position in RMD in Q4 2024 and has held it in 7 quarters since. The position peaked at $725K in Q3 2025. 887 funds tracked by Wall St. Rank hold RMD as of Q2 2026.

  • CFO4Life Group held 2,272 shares of ResMed worth $443K as of Q2 2026.
  • CFO4Life Group sold 52 ResMed shares in Q2 2026, an estimated $10.8K.
  • ResMed made up 0.06% of CFO4Life Group's portfolio in Q2 2026, its #141 holding.
  • CFO4Life Group first reported a position in ResMed in Q4 2024 and has held it in 7 quarters since.
  • CFO4Life Group's ResMed position peaked at $725K in Q3 2025.
  • 887 funds tracked by Wall St. Rank held ResMed as of Q2 2026.

Based on CFO4Life Group's 13F filing for Q2 2026, filed 12 Aug 2026.